Find Clinical Trial
Vorasidenib in combination with temozolomide (TMZ) in IDH-mutant glioma
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Astrocytoma |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S.) |
| Active substance/ Medical device |
vorasidenib |
| Active Substance Code | S095032 |
| Protocol Code | S095032-211 |
| Eu CT | 2024-513738-39-00 |
| NCT Code | NCT06478212 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
